Home Cart Sign in  
Chemical Structure| 5263-87-6 Chemical Structure| 5263-87-6

Structure of 6-Methoxyquinoline
CAS No.: 5263-87-6

Chemical Structure| 5263-87-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: p-Quinanisole

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 5263-87-6 ]

CAS No. :5263-87-6
Formula : C10H9NO
M.W : 159.18
SMILES Code : COC1=CC2=C(C=C1)N=CC=C2
Synonyms :
p-Quinanisole
MDL No. :MFCD00006800
InChI Key :HFDLDPJYCIEXJP-UHFFFAOYSA-N
Pubchem ID :14860

Safety of [ 5263-87-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 5263-87-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 10
Fraction Csp3 0.1
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 48.24
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

22.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.05
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.2
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.24
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.49
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.46
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.09

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.76
Solubility 0.274 mg/ml ; 0.00172 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.3
Solubility 0.8 mg/ml ; 0.00503 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.82
Solubility 0.0243 mg/ml ; 0.000153 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.71 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.13

Application In Synthesis of [ 5263-87-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 5263-87-6 ]

[ 5263-87-6 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 5263-87-6 ]
  • [ 6563-13-9 ]
YieldReaction ConditionsOperation in experiment
97% With dihydrogen peroxide; In water; for 0.25h;Sonication; In a 50 mL round-bottom flask, 1.59 g of 6-methoxyquinoline and then 1.1 g of hydrogen peroxide (35% by mass) were successively added.5% mass fraction of perfluorosulfonic acid resin, 10 ml of water as a solvent, and the resulting mixture in an ultrasonic reaction apparatus at 60 W/The reaction was performed for 15 minutes under 20 KHz ultrasound. The resin catalyst in the reaction system was removed by filtration, and the reaction solvent was removed under reduced pressureWater, finally recrystallized to give 1.69 g of 6-methoxyquinoline nitrous oxide in 97% yield.
90% With 3-chloro-benzenecarboperoxoic acid; In dichloromethane; at 0 - 20℃; for 24h; General procedure: To a solution of the corresponding quinoline substrate (5 mmol) in CH2Cl2 (30 mL), m-CPBA (7.5 mmol, 1.5 equiv) was added at 0 C. The reaction mixture was allowed to stir at room temperature for 24 h. Next, saturated aq NaHCO3 solution (100 mL) was added to the reaction mixture. Then, the mixture was extracted with CH2Cl2 (3 × 50 mL) and the organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel to obtain the pure quinoline N-oxide (70-90% yield).
82% With dihydrogen peroxide; In acetic acid; at 100℃; for 2h; 6-Methoxy quinoline (15 g, 0.094 mol) was dissolved in acetic acid (97 ml) and treated with hydrogen peroxide (37 ml). The mixture was stirred to 100 C. for 2 hours. After evaporation to dryness 100 ml of water was added to the residue until a precipitate appears. Filtration and washing with water gives a yellow precipitate that is dried under vacuum to yield 13.5 g of the title compound as a light yellow solid (82%). MS (m/e): 176.3 (M+H)+.
55% To a solution of 6- methoxyquinoline (2.00 g, 12.6 mmol) in AcOH (10 mL) was added Η202 (30% in water, 1.9 mL, 18.9 mmol), the mixture was heated to 70 C for 21 hours. The mixture was basified with 2M NaOH to pH 8-9 and extracted with CH2C12 (200 mL), the combined organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated to give the crude product, which was purified by silica gel column (EtOAc / MeOH=10 / 1) to give 6- methoxyquinoline 1-oxide (1.20 g, 55%) as a solid.
55% To a solution of 6- methoxyquinoline (2.00 g, 12.6 mmol) in AcOH (10 mL) was added H202 (30% in water, 1.9 mL, 18.9 mmol), the mixture was heated to 70 C for 21 hours. The mixture was basified with 2M NaOH to pH 8-9 and extracted with CH2C12 (200 mL), the combined organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated to give the crude product, which was purified by silica gel column (EtOAc / MeOH=10 / 1) to give 6- methoxyquinoline 1-oxide (1.20 g, 55%) as a solid.
With dihydrogen peroxide; In acetic acid; at 82℃; for 19h; A solution of 6-methoxyquinoline (11.21 g, 70 [MMOL)] in glacial acetic acid is treated dropwise with 30% hydrogen peroxide (15 mL) and then heated at [82C] for 19 hours. The reaction mixture is cooled, poured onto ice and carefully basified with concentrated ammonium hydroxide. The precipitate is collected, washed with hexane and dried in vacuo to provide the title compound (quantitative yield), which is used as such in the next step. MS [ (+) ES, m/z]: 176.1 [M+H] +
With 3-chloro-benzenecarboperoxoic acid; In dichloromethane; at 0 - 20℃; for 12h; General procedure: To a solution of the corresponding N-heterocycles (10.0 mmol) in CH2Cl2 (20 mL), m-chloroperoxybenzoic acid (m-CPBA, 20.0 mmol, 2.0 equiv) was added at 0 C. The reaction mixture was allowed to stir at room temperature for 12 h. Then saturated aqueous NaHCO3 (20 mL) was added. The aqueous was extracted with CH2Cl2 (10 mL x 3) and the combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with EtOAc/n-hexene or EtOAc/MeOH to afford desired N-oxides.
With 3-chloro-benzenecarboperoxoic acid; In dichloromethane; at 0 - 20℃;Inert atmosphere; General procedure: To a solution of 6-methylquinoline (270 µL, 2.0 mmol, 1.0 eq) in dry dichloromethane (4.0 mL), m-chloroperbenzoic acid (690 mg, 4.0 mmol, 2.0 eq) was added at 0 C under argon. The mixture was stirred overnight at room temperature, then diluted with dichloromethane and washed with potassium hydroxide (6 M). The organic layers were dried over magnesium sulfate, filtered and evaporated to dryness under reduced pressure. A mixture of the residue, molecular sieve (4 Å) and tetrabutylammonium bromide (967 mg, 3.0 mmol, 1.5 eq) in dry dichloromethane (200 mL) was stirred for 10 min at room temperature. p-Toluenesulfonic anhydride (979 mg, 3.0 mmol, 1.5 eq) was added and stirring was continued at room temperature overnight. The reaction mixture was filtered and the solvent was evaporated to dryness under reduced pressure. The crude product was purified by column chromatography (cyclohexane/chloroforme 10:15:11:1) to give 297 mg (1.34 mmol, 67%) of the analytically pure compound. C10H8BrN; MW: 222; 1H NMR (CDCl3, 400 MHz): δ 7.99-7.87 (m, 2H), 7.62-7.53 (m, 2H), 7.46 (d, J = 8.5 Hz, 1H), 2.52 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ 147.3, 140,9, 137.9, 137.3, 132.9, 128.4, 127.1, 126.7, 125.8, 21.7.; MS (ESI): 223 (M+H)+.
With 3-chloro-benzenecarboperoxoic acid; In dichloromethane; at 0 - 20℃; General procedure: 77% 3-chloroperbenzoic acid (m-CPBA) (3 mmol) in CH2Cl2 (5 mL) was dropped into a solutionof quinoline derivatives (2 mmol) in CH2Cl2 (5 mL) cooled to 0 under vigorous magnetic stirringfor overnight. After the completion of this course, the reaction mixture was allowed up to roomtemperature and stirred overnight. An aqueous solution of saturated NaHCO3 was added to themixture to neutralize residual m-CPBA. The resulting mixture was extracted with CH2Cl2 (3 × 10mL). The organic phase was combined and washed with saturated NaCl solution (3 × 5 mL). The organiclayer was dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure to givecrude products, which were purified by column chromatography (silica gel 200-300 mesh, AcOEt:MeOH (95:05) as eluent). The products were identified by 1H NMR and MS spectra and comparedto the previous literature.

References: [1]Patent: CN108003098,2018,A .Location in patent: Paragraph 0061; 0062; 0063.
[2]Organic Letters,2019,vol. 21,p. 3407 - 3411.
[3]Journal of the American Chemical Society,2017,vol. 139,p. 5998 - 6007.
[4]Synthesis,2019,vol. 51,p. 3313 - 3319.
[5]Organic and Biomolecular Chemistry,2019,vol. 17,p. 309 - 314.
[6]Patent: US2006/84679,2006,A1 .Location in patent: Page/Page column 12.
[7]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 4495 - 4500.
[8]Chemical and Pharmaceutical Bulletin,1980,vol. 28,p. 1157 - 1171.
[9]Organic Letters,2017,vol. 19,p. 6088 - 6091.
[10]European Journal of Organic Chemistry,2021,vol. 2021,p. 495 - 498.
[11]Patent: WO2012/48181,2012,A1 .Location in patent: Page/Page column 74.
[12]Patent: WO2012/83165,2012,A1 .Location in patent: Page/Page column 90-91.
[13]Organic and Biomolecular Chemistry,2016,vol. 14,p. 5820 - 5825.
[14]Chemistry of Heterocyclic Compounds,1981,vol. 17,p. 72 - 76.
    Khimiya Geterotsiklicheskikh Soedinenii,1981,p. 89 - 94.
[15]Zhurnal Obshchei Khimii,1937,vol. 7,p. 1896,1904.
    Chemisches Zentralblatt,1938,vol. 109,p. 3774.
[16]Journal of Organic Chemistry,1944,vol. 9,p. 302,305, 309.
[17]Gazzetta Chimica Italiana,1953,vol. 83,p. 58,60.
[18]Journal of Medicinal Chemistry,1986,vol. 29,p. 2024 - 2028.
[19]Journal of Molecular Structure,2003,vol. 661-662,p. 209 - 218.
[20]Journal of Chemical Thermodynamics,2003,vol. 35,p. 1093 - 1100.
[21]Tetrahedron Letters,2006,vol. 47,p. 8511 - 8514.
[22]Patent: WO2004/24731,2004,A1 .Location in patent: Page 55.
[23]Chemical Communications,2013,vol. 49,p. 6900 - 6902.
[24]Organic Letters,2013,vol. 15,p. 5706 - 5709.
[25]Organic Letters,2014,vol. 16,p. 1840 - 1843.
[26]European Journal of Organic Chemistry,2015,vol. 2015,p. 2133 - 2137.
[27]Chemical Communications,2015,vol. 51,p. 7035 - 7038.
[28]Chemistry - A European Journal,2015,vol. 21,p. 17200 - 17204.
[29]Organic and Biomolecular Chemistry,2016,vol. 14,p. 2613 - 2617.
[30]European Journal of Organic Chemistry,2016,vol. 2016,p. 1606 - 1611.
[31]Organic Letters,2016,vol. 18,p. 4144 - 4147.
[32]New Journal of Chemistry,2016,vol. 40,p. 10227 - 10232.
[33]Angewandte Chemie - International Edition,2016,vol. 55,p. 12891 - 12894.
    Angew. Chem.,2016,vol. 128,p. 13083 - 13086,4.
[34]European Journal of Organic Chemistry,2017,vol. 2017,p. 1025 - 1032.
[35]Organic and Biomolecular Chemistry,2017,vol. 15,p. 3165 - 3169.
[36]Journal of Organic Chemistry,2017,vol. 82,p. 8933 - 8942.
[37]Advanced Synthesis and Catalysis,2017,vol. 359,p. 3022 - 3028.
[38]Advanced Synthesis and Catalysis,2018,vol. 360,p. 905 - 910.
[39]Tetrahedron Letters,2018,vol. 59,p. 1752 - 1756.
[40]European Journal of Medicinal Chemistry,2018,vol. 155,p. 61 - 76.
[41]Organic Letters,2018,vol. 20,p. 3487 - 3490.
[42]Chemistry - An Asian Journal,2018,vol. 13,p. 2388 - 2392.
[43]Advanced Synthesis and Catalysis,2019,vol. 361,p. 520 - 525.
[44]Chemistry - A European Journal,2019,vol. 25,p. 3000 - 3004.
[45]Journal of Organic Chemistry,2019,vol. 84,p. 2786 - 2797.
[46]Journal of Organic Chemistry,2019,vol. 84,p. 6962 - 6969.
[47]Angewandte Chemie - International Edition,2019,vol. 58,p. 12950 - 12954.
    Angew. Chem.,2019,vol. 131,p. 13084 - 13088,5.
[48]Chemical Communications,2019,vol. 55,p. 11091 - 11094.
[49]Advanced Synthesis and Catalysis,2019,vol. 361,p. 5616 - 5625.
[50]Chemical Communications,2019,vol. 55,p. 13852 - 13855.
[51]Journal of Organic Chemistry,2020,vol. 85,p. 2476 - 2485.
[52]Journal of Medicinal Chemistry,2020,vol. 63,p. 1156 - 1177.
[53]Journal of Organic Chemistry,2020,vol. 85,p. 9244 - 9254.
[54]Angewandte Chemie - International Edition,2020,vol. 59,p. 17042 - 17048.
    Angew. Chem.,2020,vol. 132,p. 17190 - 17196,7.
[55]Organic Letters,2020,vol. 22,p. 7671 - 7675.
[56]Green Chemistry,2020,vol. 22,p. 6560 - 6566.
[57]Green Chemistry,2021,vol. 23,p. 490 - 495.
[58]Beilstein Journal of Organic Chemistry,2021,vol. 17,p. 485 - 493.
[59]Chemical Communications,2021,vol. 57,p. 6995 - 6998.
[60]Tetrahedron Letters,2021,vol. 83.
[61]Organic Letters,2022,vol. 24,p. 1434 - 1438.
  • 3
  • [ 5263-87-6 ]
  • [ 51323-43-4 ]
  • m-N-(boronobenzyl)-6-methoxyquinolinium bromide [ No CAS ]
  • 5
  • [ 5263-87-6 ]
  • cobalt(II) sulphate heptahydrate [ No CAS ]
  • [ 547-32-0 ]
  • Co(sulfadiazine)<SUB>2</SUB>(6-methoxyquinoline)<SUB>2</SUB> [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 5263-87-6 ]

Ethers

Chemical Structure| 1078-28-0

A138089 [1078-28-0]

6-Methoxy-2-methylquinoline

Similarity: 0.95

Chemical Structure| 783-08-4

A138879 [783-08-4]

N-Benzylidene-4-methoxyaniline

Similarity: 0.88

Chemical Structure| 52057-98-4

A247904 [52057-98-4]

6-(4-Methoxyphenyl)pyridin-3-amine

Similarity: 0.87

Chemical Structure| 14446-31-2

A490705 [14446-31-2]

6-Methoxy-3-methylisoquinoline

Similarity: 0.87

Chemical Structure| 4964-76-5

A149896 [4964-76-5]

7-Methoxyquinoline

Similarity: 0.85

Related Parent Nucleus of
[ 5263-87-6 ]

Quinolines

Chemical Structure| 1078-28-0

A138089 [1078-28-0]

6-Methoxy-2-methylquinoline

Similarity: 0.95

Chemical Structure| 4964-76-5

A149896 [4964-76-5]

7-Methoxyquinoline

Similarity: 0.85

Chemical Structure| 23432-40-8

A122877 [23432-40-8]

6-Methylquinolin-4-ol

Similarity: 0.85

Chemical Structure| 4363-94-4

A154472 [4363-94-4]

6-Methoxyquinoline-4-carbaldehyde

Similarity: 0.85

Chemical Structure| 87199-83-5

A116503 [87199-83-5]

7-Methoxyquinolin-3-amine

Similarity: 0.83